Symptomatic Control of Neuroendocrine Tumours with Everolimus

摘要: Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, increases progression-free survival in patients with advanced neuroendocrine tumours. Patients tumours and symptomatic carcinoid have inferior health-related quality life than those without symptoms. We aimed to evaluate the effect everolimus on control Fifteen metastatic disease pre-treated depot octreotide received combination (midgut = 8, pancreatic 3, other 4). Reasons for initiation were progressive (PD) by response evaluation criteria solid (n 5), worsening syndromic symptomology or both 5). Symptomatic objective toxicity evaluated using standard criteria. 7/10 who had improvements symptomology, mean duration symptom 13.9 months (range 1–39). All 10 non (pNET) primaries, everolimus, 6/10 reduced stool frequency, 3/7 reduction asthenia, 5/7 frequency severity flushing. Sixty percent experienced any grade toxicities, including following: 40 % 1/2 stomatitis, 7 3/4 20 rash, 13 diarrhoea, one case pneumonitis. In this cohort 15 patients, we demonstrated that 70 pNET individuals common syndrome symptoms resistant improvement these institution meaningful durations control. Although data is observational, our knowledge, represents largest analysis combined octreotide.